Not for distribution, directly or indirectly, in
The issuer advises that the following replaces the
The TDIM has been updated for posting to the
All other details remain unchanged.
The full corrected version is shown below.
MAINSTAY ANNOUNCES THE PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION,
INCREASING THE GROSS PROCEEDS
OF THE OFFER TO APPROXIMATELY €18.8M
Application has been made for listing and admission to trading of the 38,264 new Ordinary Shares on
Total Voting Rights
In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC) Regulations 2007 of
In accordance, with the provisions of Article 631-10 of the RÈglement gÉnÉral of the French AutoritÉ des marchÉs financiers, SociÉtÉ GÉnÉrale, acting as Stabilising Manager, declares that:
Pricing information is set forth below:
|Date||Low price||High price|
FOR FURTHER DETAILS, CONTACT:
|Joint Global Coordinators and Joint Bookrunners|
17, Cours Valmy,
|Prospectus Adviser, ESM Adviser and |
|Media & Investor Relations Adviser|
FTI Consulting (
+353 1 663 3600 or firstname.lastname@example.org
FTI Consulting (
5, Rue Scribe
This document does not constitute and shall not be considered as constituting a public offer, an offer to purchase or as an intention to solicit the interest of the public for a public offering of securities.
The information in this announcement is for background purposes only and does not purport to be accurate, full or complete. It is given at the date of its publication (unless otherwise marked) and is subject to updating, revision and amendment and no reliance may be placed for any purpose on it.
The prospectus (the "Prospectus") of
No reliance may or should be placed by any person for any purposes whatsoever on the information contained in this announcement or on its completeness, accuracy or fairness.
The distribution of this document in certain countries may be subject to specific regulations. Persons who come into possession of this press release must inform themselves of and comply with these restrictions.
This document does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in
This announcement includes statements that are, or may be deemed to be, forward looking statements. These forward looking statements can be identified by the use of forward looking terminology, including the terms “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “should” or “will”, or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward looking statements include all matters that are not historical facts. They appear throughout this announcement and include, but are not limited to, statements regarding the Company’s intentions, beliefs or current expectations concerning, among other things, the Company’s results of operations, financial position, prospects, financing strategies, expectations for product design and development, regulatory approvals, reimbursement arrangements, costs of sales and market penetration.
By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances. Forward looking statements are not guarantees of future performance and the actual results of the Company’s operations, and the development of the markets and the industry in which the Company operates, may differ materially from those described in, or suggested by, the forward looking statements contained in this announcement. In addition, even if the Company’s results of operations, financial position and growth, and the development of the markets and the industry in which the Company operates, are consistent with the forward looking statements contained in this announcement, those results or developments may not be indicative of results or developments in subsequent periods. A number of factors could cause results and developments of the Company to differ materially from those expressed or implied by the forward looking statements including, without limitation, general economic and business conditions, the global medical device market conditions, industry trends, competition, changes in law or regulation, changes in taxation regimes, the availability and cost of capital, currency fluctuations, changes in its business strategy, political and economic uncertainty and other factors to be disclosed in the Prospectus. The forward-looking statements therein speak only at the date of this announcement.